Pharma Exclusives Pressreleases
AbbVie and RemeGen Announce Exclusive Licensing Agreement to Develop A Novel Bispecific Antibody for Advanced Solid Tumors
Monday, January 12, 2026AbbVie and RemeGen today announced an exclusive licensing agreement for the development manufacturing and commercialization of RC a novel investigational Programmed Cell Death PD
Lilly to acquire Ventyx Biosciences to advance oral therapies targeting inflammatory-mediated diseases
Thursday, January 08, 2026Eli Lilly and Company and Ventyx Biosciences Inc Nasdaq VTYX a San Diegobased clinicalstage biopharmaceutical company focused on developing innovative oral therapies for patients with inflammatorymediated diseases
Merck to Complete Acquisition of Cidara Therapeutics
Wednesday, January 07, 2026Merck known as MSD outside of the United States and Canada today announced the successful completion of the cash tender offer through a subsidiary for all the outstanding shares of common stock of Cidara Therapeutics
Moderna Announces Global Regulatory Submissions for Its Investigational Seasonal Influenza Vaccine
Monday, January 05, 2026Moderna Inc today provided an update on regulatory submissions for its investigational seasonal influenza vaccine mRNA for adults aged years and older The Company has filed for marketing authorization with the US Food and Drug Administration FDA
Gilead Sciences Exercises Option to License Assembly Biosciences’ Helicase-Primase Inhibitor Programs for Recurrent Genital Herpes
Monday, December 22, 2025Gilead Sciences Inc and Assembly Biosciences Inc Nasdaq ASMB today announced Gilead has exercised its combined option to exclusively license Assembly Bios herpes simplex virus HSV
Thermo Fisher Scientific Expands Gibco™ Bacto™ Portfolio with Next-Generation, Chemically Defined Media to Boost E. coli Biomanufacturing Productivity
Monday, December 15, 2025Thermo Fisher Scientific Inc the world leader in serving science today announced the launch of Gibco Bacto CD Supreme FPM Plus and Gibco Bacto CD Supreme Feed X two nextgeneration chemicallydefined formulations that expand the Gibco Bacto
Lilly to build $6 billion facility to manufacture active pharmaceutical ingredients in Alabama
Wednesday, December 10, 2025Eli Lilly and Company today announced plans to invest more than billion in a new manufacturing facility in Huntsville Alabama This nextgeneration synthetic medicine active pharmaceutical ingredient API facility the third of four new US
Imfinzi approved in the US as first and only perioperative immunotherapy for patients with early gastric and gastroesophageal cancers
Wednesday, November 26, 2025AstraZenecas Imfinzi durvalumab in combination with standardofcare FLOT chemotherapy fluorouracil leucovorin oxaliplatin and docetaxel has been approved in the US for the treatment of adult patients with resectable
AstraZeneca plans $2 billion manufacturing investment in Maryland, supporting 2,600 jobs and catalysing economic growth
Monday, November 24, 2025AstraZeneca today announces plans to invest billion to expand its longstanding manufacturing footprint in Maryland This includes a significant expansion of its flagship biologics manufacturing facility in Frederick and construction
Biogen and Dayra Therapeutics Announce Research Collaboration to Discover and Develop Oral Macrocyclic Peptides for a Range of Immunological Conditions
Monday, November 24, 2025Biogen Incand Dayra Therapeutics today announced a research collaboration to discover and develop oral macrocyclic peptides for priority targets in immunological conditions Macrocyclic peptides have a unique profile with the potential to offer biolog...
